Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7137508 | 0.99 | LMNA (0.44) | LMNASMN1; SMN2SLC1A3SLC1A1L3MBTL1 | |
| SCHEMBL7133730 | 0.91 | CTSL (0.43) | LMNASMN1; SMN2KCNA5CASP1 | |
| SCHEMBL7135891 | 0.86 | SLC1A3 (0.42) | LMNASMN1; SMN2SLC1A3SLC1A1L3MBTL1 | |
| SCHEMBL7136868 | 0.86 | SLC1A3 (0.42) | LMNASMN1; SMN2SLC1A3SLC1A1L3MBTL1 | |
| SCHEMBL7137551 | 0.86 | SLC1A3 (0.42) | LMNASMN1; SMN2SLC1A3SLC1A1L3MBTL1 | |
| SCHEMBL7136804 | 0.86 | HTT (0.51) | LMNASMN1; SMN2SLC1A3SLC1A1L3MBTL1 | |
| SCHEMBL7131854 | 0.86 | KMT2A (0.44) | LMNASMN1; SMN2 | |
| SCHEMBL7137518 | 0.85 | CNR1 (0.49) | LMNASMN1; SMN2 | |
| SCHEMBL7139406 | 0.85 | LMNA (0.51) | LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL7136755 | 0.84 | LMNA (0.47) | LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | LMNA 2624/4885SMN1; SMN2 3977/4885SLC1A3 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.